基于深度学习的稳健PET预后影像生物标志物用于DLBCL患者的多中心研究
该回顾性多中心研究纳入三个独立医学中心的684例弥漫性大B细胞淋巴瘤(DLBCL)患者,利用VGG19和DenseNet121深度卷积神经网络从PET图像生成深度学习评分(DLS),并构建多参数模型预测无进展生存期(PFS)和总生存期(OS)。DLS与PFS、OS显著相关,多参数模型在训练队列中预测PFS的C-index为0.866、OS为0.835,外部验证队列中PFS的C-index为0.760和0.770、OS为0.748和0.766,校准曲线一致性良好,决策曲线分析显示更多净临床获益。
要点
- 基于PET图像的深度学习评分(DLS)与DLBCL患者的PFS和OS显著相关(P<0.05)。
- 多参数模型在训练队列预测PFS的C-index为0.866、OS为0.835,优于对照模型。
- 外部验证队列PFS的C-index为0.760和0.770,OS为0.748和0.766。
核心结论
- DLS被确定为DLBCL患者生存的稳健预后影像生物标志物。
- 本研究开发的多参数模型在根据生存风险准确分层患者方面展现出良好潜力。
研究设计与样本
- 回顾性研究,纳入来自三个独立医学中心的684例DLBCL患者。
- 使用VGG19和DenseNet121深度卷积神经网络架构从PET图像生成深度学习评分(DLS)。
- 基于Cox比例风险模型结果设计多参数模型,并在训练队列和验证队列中通过校准曲线、一致性指数(C-index)和决策曲线分析(DCA)进行评估。
主要发现
- DLSPFS和DLSOS分别与PFS和OS显著相关(P<0.05),在训练队列和验证队列中均如此。
- 在训练队列中,纳入DLS的多参数模型预测PFS的C-index为0.866、预测OS的C-index为0.835,优于竞争模型。
- 在外部验证队列中,PFS的C-index分别为0.760和0.770,OS的C-index分别为0.748和0.766。
- 校准曲线显示良好一致性,决策曲线分析证实多参数模型提供更多净临床获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To develop and independently externally validate robust prognostic imaging biomarkers distilled from PET images using deep learning techniques for precise survival prediction in patients with diffuse large B cell lymphoma (DLBCL). METHODS: A total of 684 DLBCL patients from three independent medical centers were included in this retrospective study. Deep learning scores (DLS) were generated from PET images using deep convolutional neural network architecture known as VGG19 and DenseNet121. These DLSs were utilized to predict progression-free survival (PFS) and overall survival (OS). Furthermore, multiparametric models were designed based on results from the Cox proportional hazards model and assessed through calibration curves, concordance index (C-index), and decision curve analysis (DCA) in the training and validation cohorts. RESULTS: The DLSPFS and DLSOS exhibited significant associations with PFS and OS, respectively (P<0.05) in the training and validation cohorts. The multiparametric models that incorporated DLSs demonstrated superior efficacy in predicting PFS (C-index: 0.866) and OS (C-index: 0.835) compared to competing models in training cohorts. In external validation cohorts, the C-indices for PFS and OS were 0.760 and. 0.770 and 0.748 and 0.766, respectively, indicating the reliable validity of the multiparametric models. The calibration curves displayed good consistency, and the decision curve analysis (DCA) confirmed that the multiparametric models offered more net clinical benefits. CONCLUSIONS: The DLSs were identified as robust prognostic imaging biomarkers for survival in DLBCL patients. Moreover, the multiparametric models developed in this study exhibited promising potential in accurately stratifying patients based on their survival risk.
引用
- Jiang C, Qian C, Jiang Z, et al. Robust deep learning-based PET prognostic imaging biomarker for DLBCL patients: a multicenter study. Eur J Nucl Med Mol Imaging. 2023. PMID: 37606859. doi:10.1007/s00259-023-06405-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。